Filtered By:
Source: Neurology
Condition: ALS
This page shows you your search results in order of date.
Order by Relevance | Date
Total 21 results found since Jan 2013.
Edaravone (MCI-186) for the Treatment of Amyotrophic Lateral Sclerosis (ALS): A Posthoc Analysis of Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) by Domain and Individual Items (P3.130)
Conclusions:A generally favorable descriptive effect for edaravone was observed during posthoc assessment of the ALSFRS-R by domain and individual items.Study Supported by: MTPC was responsible for funding and conduct of the study. MTDA was responsible for executing this analysis.Disclosure: Dr. Palumbo has received personal compensation for activities with Mitsubishi Tanabe as an employee. Dr. Palumbo holds stock options in Actelion Clinical Research, Inc., in which his spouse is a full-time pharmaceutical researcher and receives stock options as partial compensation for work performed. Dr. Takei has received personal com...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Palumbo, J. M., Takei, K., Tsuda, K., Liu, S. Tags: Neuromuscular and Clinical Neurophysiology (EMG): Motor Neuron Disease I Source Type: research
Cumulative Distribution of Amyotrophic Lateral Sclerosis Functional Rating Scale- Revised (ALSFRS-R) Scores in a Phase 3 Study of Edaravone (MCI-186) for the Treatment of Amyotrophic Lateral Sclerosis (ALS): A Posthoc Assessment (P5.110)
Conclusions:Demonstration of median shift and proportion of patients with no decline in ALSFRS-R, and those whose change in ALSFRS-R was limited to ≤2 points during 24 weeks of treatment, may appear to provide supporting evidence for the efficacy of edaravone over placebo.Study Supported by: MTPC was responsible for funding and conduct of the study. MTDA was responsible for executing this analysis.Disclosure: Dr. Takei has received personal compensation for activities with Mitsubishi Tanabe as an employee. Dr. Palumbo has received personal compensation for activities with Mitsubishi Tanabe as an employee. Dr. Palumbo ho...
Source: Neurology - April 17, 2017 Category: Neurology Authors: Takei, K., Palumbo, J. M., Tsuda, K., Liu, S. Tags: Neuromuscular and Clinical Neurophysiology (EMG) Poster Discussion Session Source Type: research
Sexuality and disability, a poorly studied relationship in neurology (P2.199)
Conclusions:Sexual dysfunction was more frequent in patients with chronic neurological diseases. We found a statistically significant relationship between sexual dysfunction and disability. For overall sexual function, the results indicate that women had lower rates of sexual performance for the same degree of disability than menDisclosure: Dr. Nasimbera has nothing to disclose. Dr. Rosales has nothing to disclose. Dr. Quarrachino has nothing to disclose. Dr. Rodriquez has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Nasimbera, A., Rosales, J., Silva, B., Alonso, R., Bohorquez, N., Lepera, S., Garreto, N., Tomoko, A., Garcea, O., Raul, R., Quarrachino, C., Rodriquez, G. Tags: General Neurology: Practice Improvement and Novel Approaches to Care Source Type: research
The Evaluation and Management of Alternative Diagnoses in Amyotrophic Lateral Sclerosis (P5.091)
Conclusions: Treatment with intravenous steroids, immunoglobulin and surgical interventions prior to diagnosis of ALS is associated with a significantly prolonged mean ODI.Disclosure: Dr. Kannan has nothing to disclose. Dr. Glass has nothing to disclose.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Kannan, M., Glass, J. Tags: Neuroepidemiology: Neuro-oncology and ALS Source Type: research
Parakinesia Brachialis Oscitans after an Acute Internal Capsule Infarct (P1.014)
Conclusions:Involuntary stereotyped movements of an otherwise plegic arm while yawning was first observed in 1844 and coined "parakinesia brachialis oscitans" in 2010. The term parakinesia was used to differentiate the movements from synkinesia. The causes are diverse and include ischemic or hemorrhagic strokes, pontine tuberculoma, and amyotrophic lateral sclerosis. Ischemic strokes are most often implicated and typically involve a lenticulostriate branch of the middle cerebral artery. Lesions affecting the pyramidal tracts are the common denominator. The phenomenon may be observed acutely when the limb is flaccid or mont...
Source: Neurology - April 3, 2016 Category: Neurology Authors: Koo, B., Wang, E. Tags: Movement Disorders ePoster Session Source Type: research
The Changing Landscape of Ethical Issues in Neurology Practice and Research (P1.365)
Conclusions: As technological advancements provide neurologists with more diagnostic and treatment options ethical considerations need to be reassessed in order to ensure adherence to medical and neurological professional codes of conduct. Many of these technological advancements have provided neurologists with tools and treatment options which although appear promising, are far from universally understood or accepted. New concerns regarding Brain death, neuro-enhancement, and TBI have emerged and merit further study.Disclosure: Dr. Bergquist has nothing to disclose. Dr. Theriault has nothing to disclose. Dr. Etienne has nothing to disclose.
Source: Neurology - April 3, 2016 Category: Neurology Authors: Bergquist, P., Theriault, M., Etienne, M. Tags: Ethics and Policy Source Type: research
PRISM II: Effectiveness of Dextromethorphan 20 mg/Quinidine 10 mg (NUEDEXTA(R)) for Treatment of Pseudobulbar Affect Secondary to Dementia, Stroke, or Traumatic Brain Injury: Combined Results of a Multicenter Open-Label Study (P2.225)
Conclusion: The open-label PRISM II study supports DM/Q effectiveness for PBA irrespective of underlying etiology. Study supported by: Avanir Pharmaceuticals, Inc.Disclosure: Dr. Siffert has nothing to disclose. Dr. Hammond has nothing to disclose. Dr. Alexander has nothing to disclose. Dr. Cutler has received personal compensation for activities with Abbott, AstraZeneca, Bristol-Myers Squibb, Forest, GlaxoSmithKline, Lilly, Merck, Novartis, Ortho-McNeil-Janssen, Otsuka, Pamlab, Pfizer, Shire, and Sunovion. Dr. D'Amico has received personal compensation for activities with Avanir Pharmaceuticals, Inc. Dr. Doody has receive...
Source: Neurology - April 3, 2016 Category: Neurology Authors: Siffert, J., Hammond, F., Alexander, D., Cutler, A., D'Amico, S., Doody, R., Sauve, W., Zorowitz, R., Davis, C., Shin, P., Ledon, F., Yonan, C., Formella, A. Tags: Aging and Dementia: Therapeutics Source Type: research
Botulinum Toxin A for Treatment of Sialorrhea in neurologic diseases: 2-year Prospective Study (P3.155)
Conclusions: This long-term prospective observational study of a wide cohort of patients confirms that ultrasonographically guided BoNT-A injections represents an effective and safe treatment for sialorrhea in different neurologic disorders.Disclosure: Dr. Barbero has nothing to disclose. Dr. Artusi has nothing to disclose. Dr. De Mercanti has nothing to disclose. Dr. Tinivella has nothing to disclose. Dr. Busso has nothing to disclose. Dr. Clerico has nothing to disclose. Dr. Durelli has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Barbero, P., Artusi, C. A., De Mercanti, S., Tinivella, M., Busso, M., Clerico, M., Durelli, L. Tags: Neuromuscular Disease: Therapeutics Source Type: research
Amyotrophic Lateral Sclerosis (ALS) with Laboratory Abnormalities of Unknown Significance (LAUS) --Where Does It Begin and Where Does It End? (P4.144)
CONCLUSIONS: Further detailed analysis of progression rate by site of onset, sex, age, treatment will require assimilation of clinic-based datasets of properly analyzed ALS-LAUS patients from multiple clinic sites. The appropriate role of IVIg in ALS-LAUS patients requires further study following explication of the natural history of these patients compared with non-ALS-LAUS patients. The determination as to whether auto-antibodies to additional antigens may play a role in the progression rate of ALS-LAUS compared with sporadic ALS needs to be systematically studied. Study Supported by: Carolinas ALS Research FundDisclosur...
Source: Neurology - April 8, 2015 Category: Neurology Authors: Brooks, B., Bravver, E., Langford, V., Alwan, M., Smith, N., Lucas, N., Nichols, M., Belcher, S., Lary, C., Nemeth, J., Russo, P., Wright, K., Ward, A., Holsten, S., Fischer, M., Bockenek, W., Desai, U., Lindblom, S. C., Pacicco, T., Sanjak, M. Tags: Neuroepidemiology: ALS Source Type: research
A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Six-Month Clinical Trial Followed by an Open-Label Extension to Evaluate the Safety, Tolerability and Clinical Endpoint Responsiveness of the Phosphodiesterase Type 4 (PDE4) Inhibitor Ibudilast (MN-166) in Subjects with Amyotrophic Lateral Sclerosis (ALS) - STEP-IBUDILAST-ALS-DB-OLE-1 (I8-1B)
CONCLUSIONS: Interim evaluation of the primary objective-safety/tolerability and secondary objective-clinical endpoint responsiveness of MN-166 60 mg/day versus placebo administered for six months with riluzole in subjects with ALS will be presented for the first 30 patients. Study Supported by: Medicinova and Carolinas ALS Research FundDisclosure: Dr. Brooks has received personal compensation for activities with Biogen Idec, Avanir Pharmaceuticals, Acorda Therapeutics, Cytokinetics, Synapse, and the National Institute of Neurological Disorders and Stroke. Dr. Bravver has nothing to disclose. Dr. Sanjak has nothing to disc...
Source: Neurology - April 8, 2015 Category: Neurology Authors: Brooks, B., Bravver, E., Sanjak, M., Langford, V., Lary, C., Alwan, M., Nemeth, J., Russo, P., Smith, N., Lucas, N., Nichols, M., Belcher, S., Wright, K., Ward, A., Holsten, S., Fischer, M., Bockenek, W., Desai, U., Lindblom, S. C., Pacicco, T., Matsuda, Tags: Advances in ALS and Other Motor Neuron Diseases Data Blitz Presentations Source Type: research
A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Six-Month Clinical Trial Followed by an Open-Label Extension to Evaluate the Safety, Tolerability and Clinical Endpoint Responsiveness of the Phosphodiesterase Type 4 (PDE4) Inhibitor Ibudilast (MN-166) in Subjects with Amyotrophic Lateral Sclerosis (ALS) - STEP-IBUDILAST-ALS-DB-OLE-1 (S50.005)
CONCLUSIONS: Interim evaluation of the primary objective-safety/tolerability and secondary objective-clinical endpoint responsiveness of MN-166 60 mg/day versus placebo administered for six months with riluzole in subjects with ALS will be presented for the first 30 patients. Study Supported by: Medicinova and Carolinas ALS Research FundDisclosure: Dr. Brooks has received personal compensation for activities with Biogen Idec, Avanir Pharmaceuticals, Acorda Therapeutics, Cytokinetics, Synapse, and the National Institute of Neurological Disorders and Stroke. Dr. Bravver has nothing to disclose. Dr. Sanjak has nothing to disc...
Source: Neurology - April 8, 2015 Category: Neurology Authors: Brooks, B., Bravver, E., Sanjak, M., Langford, V., Lary, C., Alwan, M., Nemeth, J., Russo, P., Smith, N., Lucas, N., Nichols, M., Belcher, S., Wright, K., Ward, A., Holsten, S., Fischer, M., Bockenek, W., Desai, U., Lindblom, S. C., Pacicco, T., Matsuda, Tags: Treatment Trials in Neuromuscular Diseases Source Type: research
Emerging Subspecialties in Neurology: Neuropalliative care
Palliative medicine, as defined by World Health Organization, is the specialty that recognizes and attempts to prevent or alleviate physical, social, psychological, and spiritual suffering.1 Understanding the principles of palliative care should be an essential component of neurologic training, as the trajectory of many neurologic illnesses is progressive and incurable.2 Given the delicate nature of many of the conversations that neurologists have with patients at the time of diagnosis or during acute illness and hospitalization, expertise in discussing a patient's wishes, handling difficult conversations, and providing ad...
Source: Neurology - May 26, 2014 Category: Neurology Authors: Robinson, M. T., Barrett, K. M. Tags: Palliation pain, Palliative care RESIDENT AND FELLOW SECTION Source Type: research
Use of Veterans Specific Activity Questionnaire VSAQ to Estimate Exercise Tolerance in Ambulatory Amyotrophic Lateral Sclerosis (ambALS) Patients (P2.071)
CONCLUSIONS:VSAQ is a practical tool to estimate exercise capacity of ambALS and may be used for safe exercise prescription.Disclosure: Dr. Sanjak has nothing to disclose. Dr. Headen has nothing to disclose. Dr. Barrett has nothing to disclose. Dr. Holsten has nothing to disclose. Dr. Langford has nothing to disclose. Dr. Bravver has received research support from Biogen Idec, Avanier, Cytokinetics Pharmaceuticals, Neuraltus Pharmaceuticals, GlaxoSmithKline Inc., the National Institute of Neurological Disorders and Stroke, and the Clinical Research Consortium. Dr. Bockenek has nothing to disclose. Dr. Desai has received pe...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Sanjak, M., Headen, J., Barrett, K., Holsten, S., Langford, V., Bravver, E., Bockenek, W., Desai, U., Story, J. S., Lindblom, S. C., Paccico, T., Brooks, B. Tags: ALS: Genetics and Outcomes Source Type: research
Relationship Between Bone Mass And Muscle Weakness In Chronic Neurological Diseases (P3.036)
Conclusions: This study demonstrates greater commitment tendency to bone density in regions with weakness, compared to those without it, this could be related to disuse. This series had insufficient vitamin D. The neurologist should consider bone mass evaluation in patients with chronic muscle weakness.Disclosure: Dr. Gutierrez has nothing to disclose. Dr. Rodriguez has nothing to disclose. Dr. Garcea has nothing to disclose. Dr. Rey has nothing to disclose. Dr. Lepera has nothing to disclose. Dr. Monica has nothing to disclose. Dr. Monica has nothing to disclose. Dr. Eduardo has nothing to disclose. Dr. Berenice has nothing to disclose.
Source: Neurology - April 9, 2014 Category: Neurology Authors: Gutierrez, M., Rodriguez, G. E., Garcea, D., Rey, R., Lepera, S., Monica, E., Monica, D., Eduardo, K., Berenice, S. Tags: General Neurology II Source Type: research
Walking Capacity WalkCap Measured by Six-Minute Walk (6MW) Does Not Demonstrate Fatigue in Patients with Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS),and Parkinson Disease (PD) (P3.071)
CONCLUSIONS:WalkCap of ambulatory ALS, MS, and PD during 6MW is not affected by motor fatigue. WalkCap was higher in ambulatory patients with stronger grip, faster in TUG and 25FW. WalkCap measured by 6MW can be used as a simple outcome measure to evaluate lower extremity impairments in various neurological diseases. Discordance between WalkCap and the UPDRS-motor scale in mildly affected PD patients indicates that 6MW may provide additional information regarding these patients in clinical practice and clinical research trials.Study Supported by:Carolinas ALS Research Fund, Pinstripes Fund, Carolinas Healthcare Foundation,...
Source: Neurology - April 9, 2014 Category: Neurology Authors: Sanjak, M., Morgan, L., Simpson, A., Holsten, S., Hirsch, M., Englert, D., Iyer, S., Conway, J., Kaufman, M., Bravver, E., Desai, U., Russo, P., Brooks, B. Tags: Movement Disorders: Assessing Parkinson ' s Disease Source Type: research
